{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-021846","form_type":"8-K","ticker":"VIR","cik":"0001706431","company_name":"Vir Biotechnology, Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.776596+00:00","generated_at":"2026-06-22T09:29:05.753525+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Vir Biotech Q3 revenue $374.6M; BARDA contract up to $1B; Phase 2 data in 2023","bullets":["Q3 2022 revenue $374.6M (vs $103.6M YoY); net income $175.3M ($1.32 basic EPS) vs $110.4M ($0.85) in Q3 2021.","BARDA awards contract for pandemic preparedness: initial ~$55M, potential up to $1B.","GSK opted-in to collaborate on RSV antibodies; profit-sharing from GSK $291.2M in Q3.","Phase 2 trials for HBV, HDV (SOLSTICE), influenza A (PENINSULA); initial data expected in 2023.","Strong balance sheet: ~$2.7B cash, investments, and profit-share payments."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-021846","json":"https://secwatch.observer/filing/0000950170-22-021846.json","markdown":"https://secwatch.observer/filing/0000950170-22-021846.md","text":"https://secwatch.observer/filing/0000950170-22-021846.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1706431/000095017022021846/0000950170-22-021846-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1706431/000095017022021846/vir-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T09:29:05.753525+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c9289d08fbad7e972945f791b7406bdba2ee2ad8","claim":"Vir Biotechnology, Inc. reported financial results for third quarter ended September 30, 2022.","evidence_excerpt":"On November 3, 2022, Vir Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1706431/000095017022021846/0000950170-22-021846-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}